文献速递眼底病与葡萄膜炎

VEGF-A与VEGFR-2基因多态性与抗VEGF药物治疗新生血管性年龄相关性黄斑变性疗效的关联:一项Meta分析

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.
PubMed 文献 · Br J Ophthalmol · 2016-10-21

该Meta分析探讨VEGF-A及VEGFR-2基因多态性对新生血管性年龄相关性黄斑变性(nAMD)抗VEGF治疗反应的药物遗传学影响。结果显示,VEGF-A位点rs833061与抗VEGF治疗反应较好相关,尤其在亚洲人群中,且在以雷珠单抗(RBZ)单药方案或视力(VA)作为标准化疗效评估时更为明显;其余8个多态性未检出与治疗反应的关联。

要点

  • VEGF-A rs833061与nAMD抗VEGF治疗反应较好相关(CC vs TT:OR=2.222)。
  • 亚洲人群中rs833061关联更明显(CC vs TT:OR=2.903)。
  • 其余8个VEGF-A/VEGFR-2多态性未检出与治疗反应的关联。

核心结论

  • VEGF-A多态性rs833061的药物遗传学可能对抗VEGF治疗nAMD的反应起正向作用。

研究设计与样本

  • 本研究为一项Meta分析,聚焦VEGF相关基因多态性与nAMD抗VEGF治疗反应之间的关系。

主要发现

  • 对于VEGF-A和VEGFR-2内的单核苷酸多态性(SNPs),携带rs833061的nAMD患者抗VEGF治疗更有效(CC vs TT:OR=2.222,95%CI 1.252至3.944,p=0.006;CT vs TT:OR=2.537,95%CI 1.478至4.356,p=0.001;CC vs CT+TT:OR=2.362,95%CI 1.414至3.946,p=0.001)。
  • 在亚洲人群中rs833061关联更明显(CC vs TT:OR=2.903,95%CI 1.150至7.330,p=0.024;CT vs TT:OR=3.849,95%CI 1.522至9.733,p=0.004;CC vs CT+TT:OR=3.339,95%CI 1.369至8.145,p=0.008)。
  • 亚组分析中,仅在采用雷珠单抗(RBZ)单药方案或以视力(VA)作为标准化疗效评估时,rs833061更可能是抗VEGF治疗反应的预测因子。
  • 其余8个多态性未检出与抗VEGF治疗反应的关联。

关键数值与推荐

  • rs833061 CC vs TT:OR=2.222,95%CI 1.252至3.944,p=0.006。
  • rs833061 CT vs TT:OR=2.537,95%CI 1.478至4.356,p=0.001。
  • rs833061 CC vs CT+TT:OR=2.362,95%CI 1.414至3.946,p=0.001。
  • 亚洲人群rs833061 CC vs TT:OR=2.903,95%CI 1.150至7.330,p=0.024;CT vs TT:OR=3.849,95%CI 1.522至9.733,p=0.004;CC vs CT+TT:OR=3.339,95%CI 1.369至8.145,p=0.008。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The purpose of this study is to investigate whether gene polymorphisms of the vascular endothelial growth factor A (VEGF-A) and its receptor (VEGFR-2) have a pharmacogenetics effect on the anti-VEGF treatment for neovascular age-related macular degeneration (nAMD). METHODS: We carried out a meta-analysis focusing on the relationship between VEGF-related gene polymorphisms and treatment response of nAMD. RESULTS: For the single nucleotide polymorphisms (SNPs) within VEGF-A and VEGFR-2, anti-VEGF treatment was much more effective in patients with nAMD having rs833061 (CC vs TT:OR=2.222, 95% CI 1.252 to 3.944, p=0.006; CT vs TT: OR=2.537,95% CI 1.478 to 4.356, p=0.001 and CC vs CT+TT: OR=2.362, 95% CI 1.414 to 3.946, p=0.001), particularly for Asians (CC vs TT: OR=2.903, 95% CI 1.150 to 7.330, p=0.024; CT vs TT: OR=3.849, 95% CI 1.522 to 9.733, p=0.004 and CC vs CT+TT: OR=3.339, 95% CI 1.369 to 8.145, p=0.008, respectively). In subgroup analysis, rs833061 was more likely to be a predictor of response to anti-VEGF therapy specifically when ranibizumab (RBZ) only regime was adopted or visual acuity (VA) was taken as the standardised assessment of outcome. No association with response to anti-VEGF treatment was detected for the other eight polymorphisms. CONCLUSIONS: Pharmacogenetics of VEGF-A polymorphism rs833061 may play a positive role in response to anti-VEGF therapy for nAMD.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wu M, Xiong H, Xu Y, et al. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. Br J Ophthalmol. 2016. PMID: 28400373. doi:10.1136/bjophthalmol-2016-309418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。